Evidence map›Paper›PMID 35754072›Full record

ReviewIntensive care medicine experimental2022

Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases.

Davide Signori, Aurora Magliocca, Kei Hayashida, Jan A Graw, Rajeev Malhotra, Giacomo Bellani, Lorenzo Berra, Emanuele Rezoagli

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Intensive care medicine experimental, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06702553 (Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06702553 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)

TypeinterventionalSponsorXijing HospitalRan2025 to 2029Enrolled3,650ConditionsNitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary BypassArmsNitric Oxide Gas, Standard Care Arm
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Frontiers in immunology · 2025
    Review
  9. The Implications of Aging on Vascular Health.International journal of molecular sciences · 2024
    Review
  10. Evaluation of Nitric Oxide-Donating Properties of 11Molecules (Basel, Switzerland) · 2024
    Article
  11. Article
  12. Review
  13. NO Addition during Gas Oxygenation Reduces Liver and Kidney Injury during Prolonged Cardiopulmonary Bypass.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Davide SignoriSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Aurora MaglioccaDepartment of Medical Physiopathology and Transplants, University of Milan, Milan, Italy.
Kei HayashidaLaboratory for Critical Care Physiology, Feinstein Institutes for Medical Research, Northwell Health System, Manhasset, NY, USA.
Jan A GrawDepartment of Anesthesiology and Operative Intensive Care Medicine, CCM/CVK Charité, Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Rajeev MalhotraDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Giacomo BellaniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Lorenzo Berra *Harvard Medical School, Boston, MA, USA.
Emanuele Rezoagli *School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. emanuele.rezoagli@unimib.it.
Azienda Ospedaliera San Gerardo · ITHarvard University · USFeinstein Institute for Medical Research · USFreie Universität Berlin · DEUniversity of Milan · ITUniversity of Milano-Bicocca · IT

Funding

The Role of Histone Deacetylase 9 in Vascular CalcificationR01HL142809 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MALHOTRA, RAJEEV · 2018 to 2022
$4.0M
Hemolysis and Nitric OxideK23HL128882 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BERRA, LORENZO · 2017 to 2021
$1.0M
NHLBI NIH HHS K23 HL128882NHLBI NIH HHS R01HL142809
6 · The paper itself

Abstract

Nitric oxide (NO) is a key molecule in the biology of human life. NO is involved in the physiology of organ viability and in the pathophysiology of organ dysfunction, respectively. In this narrative review, we aimed at elucidating the mechanisms behind the role of NO in the respiratory and cardio-cerebrovascular systems, in the presence of a healthy or dysfunctional endothelium. NO is a key player in maintaining multiorgan viability with adequate organ blood perfusion. We report on its physiological endogenous production and effects in the circulation and within the lungs, as well as the pathophysiological implication of its disturbances related to NO depletion and excess. The review covers from preclinical information about endogenous NO produced by nitric oxide synthase (NOS) to the potential therapeutic role of exogenous NO (inhaled nitric oxide, iNO). Moreover, the importance of NO in several clinical conditions in critically ill patients such as hypoxemia, pulmonary hypertension, hemolysis, cerebrovascular events and ischemia-reperfusion syndrome is evaluated in preclinical and clinical settings. Accordingly, the mechanism behind the beneficial iNO treatment in hypoxemia and pulmonary hypertension is investigated. Furthermore, investigating the pathophysiology of brain injury, cardiopulmonary bypass, and red blood cell and artificial hemoglobin transfusion provides a focus on the potential role of NO as a protective molecule in multiorgan dysfunction. Finally, the preclinical toxicology of iNO and the antimicrobial role of NO-including its recent investigation on its role against the Sars-CoV2 infection during the COVID-19 pandemic-are described.

Indexed as

Blood transfusionBrain disorderCardiac arrestCardiopulmonary bypassEndothelial dysfunctionHemolysisIschemia reperfusionNitric oxidePulmonary hypertensionShuntToxicology

Identifiers

PMID35754072
PMCPMC9234017
OpenAlexW4283577195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.